therapeutic agent – Communicable Diseases Research

Zinc pyrithione is a potent inhibitor of PL Pro and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication

아연 피리티온은 SARS-CoV-2 진입 및 복제를 생체 외에서 억제하는 PL Pro 및 카텝신 L 효소의 강력한 억제제입니다.

Article

Published on 2022-12-012022-09-11
Journal: Journal of Enzyme Inhibition and Medicinal Chemist
[Category] COVID19(2023년), SARS, 치료제,

COVID-19: imbalanced cell-mediated immune response drives to immunopathology

Article

Published on 2022-12-012022-11-15
Journal: Emerging Microbes & Infections
[Category] COVID19(2023년), SARS, 치료제,

[키워드] acute respiratory syndrome alveolar damage Antiviral caused cell-mediated immune cell-mediated immune response changes in consequence coronavirus coronavirus disease COVID-19 Critical cytokine Cytokine storm effective Endotheliitis exacerbated excessive inflammation fluid overload homeostasis Host host cells immune immune responses immune system Immunological response immunopathology Inflammatory response Invasion involved lung damage Lung injury manifested mechanism NETs neutrophil activation organs pandemic Pathogenesis pathogenesis. pathophysiological progression SARS-CoV-2 SARS-CoV-2-specific immune responses severe disease syndrome therapeutic agent Therapeutic strategies tissue Trigger viral infection
[DOI] 10.1080/22221751.2022.2122579 PMC 바로가기

SARS-CoV-2 cell entry beyond the ACE2 receptor

Article

Published on 2022-11-012022-11-16
Journal: Molecular biology reports
[Category] COVID19(2023년), SARS, 변종,

Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study

Article

Published on 2022-10-212022-11-15
Journal: Medicine
[Category] COVID19(2023년), SARS, 진단,

[키워드] acute respiratory syndrome addition Analysis analyzed Antibody titer attenuate Baricitinib BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 vaccine Combination controls coronavirus coronavirus disease COVID-19 COVID-19 vaccine disease domain dose Glucocorticoids healthy volunteer humoral immune response immunomodulatory Immunosuppressant immunosuppressants immunosuppressive immunosuppressive agent Immunosuppressive medication impair inhibitor inhibitors interleukin-17 interleukin-6 investigated Japanese Kagawa methotrexate much lower Necrosis of BNT162b2 Outpatient Patient patients treated reduced rheumatic disease SARS-CoV-2 SARS-CoV-2 spike protein second dose serum serum antibody significantly significantly lower Spike protein the patient therapeutic agent Treatment university Vaccine
[DOI] 10.1097/MD.0000000000031288 PMC 바로가기

Abrogation of neutrophil inflammatory pathways and potential reduction of neutrophil-related factors in COVID-19 by intravenous immunoglobulin

Article

Published on 2022-10-202022-11-15
Journal: Frontiers in Immunology
[Category] 진단,

[키워드] abrogation Activation acute respiratory distress addition Alter ARDS cell-free DNA circulation Clinical treatment Corticosteroids Course COVID-19 COVID-19 patient Critically ill Dexamethasone dose-dependent elevated Ex vivo Factor functions healthy controls healthy donor healthy donors IL-8 inflammatory pathway Intravenous immunoglobulin Intravenous immunoglobulin (IVIG) lack Level Lung injury lung parenchyma modulate NET NETosis NETs neutrophil Neutrophil elastase Neutrophil extracellular trap neutrophil function Neutrophils not affect oxidative oxidative burst Patient Peripheral blood phagocytosis PMA pro-inflammatory function Proteins reactive oxygen specy reduced reduction severity syndrome targeting therapeutic therapeutic agent Tocilizumab tocilizumab. treated Treatment were assessed while with COVID-19
[DOI] 10.3389/fimmu.2022.993720 PMC 바로가기

Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors

선택적인 SARS-CoV/SARS-CoV-2 파파인 유사 프로테아제 억제제의 설계 및 개발을 위한 특권적인 백본인 Chalcone-amide

Review

Published on 2022-10-052022-09-11
Journal: European journal of medicinal chemistry
[Category] COVID19(2023년), SARS, 치료제,

[키워드] active site acute respiratory syndrome acute respiratory syndrome coronavirus amide antiviral immune responses backbone binding carbon caused chalcone Chalcone amide (N-benzylbenzamide) complex Compound coronavirus COVID-19 COVID-19 pandemic Critical crystal structure effort functional Genetic Host immune responses in some increase Infection inhibitor inhibitors inhibitory potency introduced maturation methyl group Papain Papain-like protease Papain-like protease (PLpro) performed PLPro polyproteins protease Protein Regulation Replication reported Research SAR SARS-CoV SARS-CoV-2 Screening selective shown similarity Structure therapeutic agent therapeutic agents Treatment treatment of COVID-19 understanding unique X-ray X-ray crystal structure.
[DOI] 10.1016/j.ejmech.2022.114572 PMC 바로가기 [Article Type] Review

In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease

Article

Published on 2022-09-272022-11-15
Journal: Molecules
[Category] SARS, 치료제,

Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial

Article

Published on 2022-09-202022-11-16
Journal: Trials
[Category] SARS, 변종,

[키워드] acute lung injury acute respiratory distress addition adverse effects antibody applied ARDS Aviptadil baseline Clinical improvement clinical status Concentration conducted COVID-19 COVID-19 in patient COVID-19 patient defined double-blinded Efficacy and safety Europe exclusion criteria FIVE hemodynamic instability high risk homeostasis hospital discharge Hospitalization immunomodulating IMPROVE indicate Inhaled intensive care intestinal intravenously lung lung tissue management mechanical ventilation metabolism Mortality multicenter Multicenter trial pandemic Pathways Patient patients hospitalized peptide placebo-controlled Prevent primary endpoint pro-inflammatory Prognosis Protein Public Hospital Randomized randomized trial Randomly reduction Regulation respiratory complication Risk factors SARS-CoV-2 severe disease course shown standard care stratified Study protocol suggested syndrome the SARS-CoV-2 therapeutic agent Therapies therapy Treatment unique vaccination Vaccine variants of SARS-CoV-2 Vasoactive VIP VIP. with COVID-19 World Health Organization
[DOI] 10.1186/s13063-022-06723-w PMC 바로가기

Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach

Article

Published on 2022-09-142022-11-15
Journal: International Journal of Molecular Sciences
[Category] SARS, 치료제,

[키워드] Activation Antiviral assist binding cascade cell damage cell membrane components COVID-19 COVID-19 infection Cytokines Defense downregulate drug expression facilitate food help highlight host cells immune immune signature immune system in viral Infection Inflammation Inflammation. inflammatory chemokine Inflammatory response innate immune response innate immune system interfere intracellular signaling involved ligands mechanism mediation modulate molecular pathogen invasion pathogenic Protein recognizing responsible RNA SARS-CoV-2 signaling pathway therapeutic agent therapeutic approach TLR TLR agonists TLRs Toll-like receptor type 1 interferon
[DOI] 10.3390/ijms231810716 PMC 바로가기

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)

Article

Published on 2022-09-042022-11-15
Journal: Journal of Translational Medicine
[Category] 바이오마커, 유전자 메커니즘,

[키워드] Accuracy addition adjuvant advance adverse events Algorithm anti-CTLA-4 Anti-PD-1 approach approved Biomarker Biomarkers biopsy BRAF BRAF inhibitor bridge cancers Cell characterized Chemotherapy clinically Combination Combination strategies combination therapy combination treatment COVID-19 pandemic development Diagnosis Drug administration Efficacy effort Evidence feature genomic help Host immune response immune Immune checkpoint inhibitor immune response Immunotherapy improve diagnostics Improved Italy lesions management mechanism mechanism of action MEK inhibitor Melanoma Naples Neoadjuvant oncogenic overcome Patient patients platform Precision predict Predictive Radiotherapy Research robust specific treatment survival systemic and local target target therapy. tested therapeutic therapeutic agent therapy translational treatment regimens tumor immunity tumor microenvironment Vaccine viruses
[DOI] 10.1186/s12967-022-03592-4 PMC 바로가기